Juvaris BioTherapeutics Starts Early Test of Flu Vaccine Enhancement

Juvaris BioTherapeutics Inc. started an early stage clinical trial of a treatment meant to enhance the effects of influenza vaccines. The drug, JVRS-100, is a so-called "adjuvant," a product that stimulates the immune system to respond more strongly to a vaccine.
San Francisco Business Times